Dominic Martin Etienne Page
Direktor/Vorstandsmitglied bei Abcam (US) Ltd.
Profil
Dominic Martin Etienne Page has held positions as Treasurer & Director at Firefly BioWorks, Inc. and Director at Abcam (US) Ltd.
Aktive Positionen von Dominic Martin Etienne Page
| Unternehmen | Position | Beginn |
|---|---|---|
Abcam (US) Ltd.
 Abcam (US) Ltd. Financial ConglomeratesFinance Part of Abcam Plc, Abcam (US) Ltd. functions as an investment holding British company. The company is based in Cambridge, UK and was founded in 2012. | Direktor/Vorstandsmitglied | 26.03.2019 |
Firefly BioWorks, Inc.
 Firefly BioWorks, Inc. Medical SpecialtiesHealth Technology Firefly BioWorks, Inc. develops an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed assays on standard laboratory instrumentation. It offers Multiplex Cellular miRNA and Multiplex Circulating miRNA Assays that use Firefly particle technology to enable simultaneous analysis of 68 miRNAs per well; and vacuum manifold for 96 well filter plates. The company was founded by Davide M. Marini and Daniel C. Pregibon in 2009 and is headquartered in Cambridge, MA. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Abcam (US) Ltd.
Abcam (US) Ltd. Financial ConglomeratesFinance Part of Abcam Plc, Abcam (US) Ltd. functions as an investment holding British company. The company is based in Cambridge, UK and was founded in 2012. | Finance |
Firefly BioWorks, Inc.
Firefly BioWorks, Inc. Medical SpecialtiesHealth Technology Firefly BioWorks, Inc. develops an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed assays on standard laboratory instrumentation. It offers Multiplex Cellular miRNA and Multiplex Circulating miRNA Assays that use Firefly particle technology to enable simultaneous analysis of 68 miRNAs per well; and vacuum manifold for 96 well filter plates. The company was founded by Davide M. Marini and Daniel C. Pregibon in 2009 and is headquartered in Cambridge, MA. | Health Technology |
